Warning letter
ChiRhoClin, Inc.: warning letter of Apr 28, 2004
FDA warning letter UCM146362 · Baltimore District Office
Key facts
| Reference number | UCM146362 |
|---|---|
| Company | ChiRhoClin, Inc. |
| Subject | Postmarketing Adverse Drug Experience Reporting Requirements |
| Issue date | Apr 28, 2004 |
| Posted date | Apr 28, 2004 |
| Issuing office | Baltimore District Office |
| Product type | Drugs |
| CFR sections cited | 314.80, 314 |
| Country | 3 |
| Inspection city | Burtonsville |
| Inspection ZIP | 20866-6129 |
| Inspection start date | Feb 9, 2004 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: